Affiliation:
1. Health Data Research Center National Taiwan University Taipei Taiwan
2. Epidemiology and Biostatistics, Master of Public Health (MPH) Boston University School of Public Health Boston Massachusetts USA
3. Department of Epidemiology Harvard T.H. Chan School of Public Health Boston Massachusetts USA
Abstract
AbstractPurposeTo compile validation findings of diagnosis codes and related algorithms for health outcomes of interest from National Health Insurance (NHI) or electronic medical records in Taiwan.MethodsWe carried out a literature review of English articles in PubMed® and Embase from 2000 through July 2022 with appropriate search terms. Potentially relevant articles were identified through review of article titles and abstracts, full text search of methodology terms “validation”, “positive predictive value”, and “algorithm” in Subjects & Methods (or Methods) and Results sections of articles, followed by full text review of potentially eligible articles.ResultsWe identified 50 published reports with validation findings of diagnosis codes and related algorithms for a wide range of health outcomes of interest in Taiwan, including cardiovascular diseases, stroke, renal impairment, malignancy, diabetes, mental health diseases, respiratory diseases, viral (B and C) hepatitis, and tuberculosis. Most of the reported PPVs were in the 80% ~ 99% range. Assessment of algorithms based on ICD‐10 systems were reported in 8 articles, all published in 2020 or later.ConclusionsInvestigators have published validation reports that may serve as empirical evidence to evaluate the utility of secondary health data environment in Taiwan for research and regulatory purpose.
Subject
Pharmacology (medical),Epidemiology
Reference101 articles.
1. U.S. Food and Drug Administration.Framework for FDA's Real‐World Evidence Program. December 2018 (Accessed Jan 4 2023).https://www.fda.gov/media/120060/download
2. U.S. Food and Drug Administration.Real‐world data: assessing electronic health records and medical claims data to support regulatory decision‐ making for drug and biological products. Draft Guidance September 2021. (Accessed Jan 4 2023).https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/real‐world‐data‐assessing‐electronic‐health‐records‐and‐medical‐claims‐data‐support‐regulatory
3. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis
4. Gastric and Duodenal Safety of Daily Alendronate
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献